TY - JOUR
T1 - Epidemiology and clinical manifestations of mucormycosis
AU - Petrikkos, George
AU - Skiada, Anna
AU - Lortholary, Olivier
AU - Roilides, Emmanuel
AU - Walsh, Thomas J.
AU - Kontoyiannis, Dimitrios P.
N1 - Funding Information:
Potential conflicts of interest. G. P. has received grant support from Gilead, Pfizer, Schering Plough, Aventis, and Merck Sharp & Dohme (MSD); has acted as a paid consultant to Janssen Cilag, Gilead, Astellas, and Schering Plough; and is a member of the speakers bureaus for Gilead, Schering Plough, and MSD. E.R. has received grant support from Pfizer, Gilead, Enzon, Schering, and Wyeth; has acted as a paid consultant to Schering, Gilead, Astellas, and Pfizer; and is a member of the speakers bureaus for Gilead, Cephalon, Pfizer, Wyeth, Schering, Merck, Aventis, and Astellas. T. J. W. has received grant support from Novartis, Astellas and is a consultant for Trius, iCo, Sigma Tau, and Draius. D. P. K. has received research support and honoraria from Merck, Pfizer, Fujisawa Pharmaceutical, and Enzon Pharmaceuticals and serves on the advisory boards for Merck and Schering-Plough Research Institute. All other authors report no potential conflicts.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Mucormycosis is an emerging angioinvasive infection caused by the ubiquitous filamentous fungi of the Mucorales order of the class of Zygomycetes. Mucormycosis has emerged as the third most common invasive mycosis in order of importance after candidiasis and aspergillosis in patients with hematological and allogeneic stem cell transplantation. Mucormycosis also remains a threat in patients with diabetes mellitus in the Western world. Furthermore, this disease is increasingly recognized in recently developed countries, such as India, mainly in patients with uncontrolled diabetes or trauma. Epidemiological data on this type of mycosis are scant. Therefore, our ability to determine the burden of disease is limited. Based on anatomic localization, mucormycosis can be classified as one of 6 forms: (1) rhinocerebral, (2) pulmonary, (3) cutaneous, (4) gastrointestinal, (5) disseminated, and (6) uncommon presentations. The underlying conditions can influence clinical presentation and outcome. This review describes the emerging epidemiology and the clinical manifestations of mucormycosis.
AB - Mucormycosis is an emerging angioinvasive infection caused by the ubiquitous filamentous fungi of the Mucorales order of the class of Zygomycetes. Mucormycosis has emerged as the third most common invasive mycosis in order of importance after candidiasis and aspergillosis in patients with hematological and allogeneic stem cell transplantation. Mucormycosis also remains a threat in patients with diabetes mellitus in the Western world. Furthermore, this disease is increasingly recognized in recently developed countries, such as India, mainly in patients with uncontrolled diabetes or trauma. Epidemiological data on this type of mycosis are scant. Therefore, our ability to determine the burden of disease is limited. Based on anatomic localization, mucormycosis can be classified as one of 6 forms: (1) rhinocerebral, (2) pulmonary, (3) cutaneous, (4) gastrointestinal, (5) disseminated, and (6) uncommon presentations. The underlying conditions can influence clinical presentation and outcome. This review describes the emerging epidemiology and the clinical manifestations of mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=84855869146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855869146&partnerID=8YFLogxK
U2 - 10.1093/cid/cir866
DO - 10.1093/cid/cir866
M3 - Article
C2 - 22247442
AN - SCOPUS:84855869146
SN - 1058-4838
VL - 54
SP - S23-S34
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 1
ER -